EL.En. S.p.A. (ELN) Earnings Call Transcript & Summary
March 14, 2025
Earnings Call Speaker Segments
Nicola Fiore
operatorGood afternoon, everyone, and welcome to the conference call on EL.En's Final Year 2024 Financial Results. This call is being recorded, and there will also be a chance to ask questions at the end of it. Joining me are Andrea Cangioli, EL.En's CEO, and Enrico Romagnoli, EL.En's Chief Financial Officer and Investor Relator. Before we start, please be aware that what management says on this call regarding future expectations, strengths and prospects constitutes forward-looking statements. Some statements made today, including those dealing with the company's beliefs, plans, objectives, estimates or expectations of possible future results or events, are forward-looking statements. Such forward-looking statements carry known or unknown risks, among them general economic and business conditions and conditions in the industry in which the company operates, and they may be affected if the assumptions prove inaccurate. As a result, no forward-looking statement can be guaranteed, and actual future results, performance or achievements could differ materially from those expressed or implied by these forward-looking statements. The company assumes no obligation regarding their contents nor to update the forward-looking statements to reflect events or circumstances that may arise after today's date. <<operator_script>>. At this point, I would like to hand the floor to Andrea Cangioli.
Nicola Fiore
operatorAndrea, please go ahead.
Andrea Cangioli
executiveGood morning, good afternoon. Thank you very much, Nicola. Thank you very much, Bianca. And thank you to all the attendees for joining this conference call we are holding after the release of the Q4 2024 and of the full year financial reports after yesterday's meeting of our Board of Directors. On the call with me, as usual, Enrico Romagnoli that will give you the appropriate highlights on our financial performance. The fourth quarter of 2024 was no exception to the business trend outlined throughout the year with a consistent pattern over the quarters. The medical business started the year slowly and progressively accelerated. Within the Industrial sector, the cutting business suffered throughout the year with strong headwinds that at this point, we could define a downturn in the markets that we consider its domestic markets, Italy and China, respectively. The rest of the Industrial business performance was slightly below expectation, mainly due to the weakness again of the Italian market. As you know, we are in a transition phase in our Industrial business. With the press release dated November 8, 2024, we disclosed our intention to transfer to the Wuhan-based Chinese Corporation YOFC, the control of what we refer to as our laser metal cutting business units.
Andrea Cangioli
executiveWe had a conference call about this matter to go through the specifics. In the follow-up update that came out on January 2, 2025, we made known that the proposed deal would no longer include the sale of a majority stake in Cutlite Penta, and that the majority sale would instead concern Penta Laser Zhejiang and our Chinese entities operating in the cutting business only. YOFC's participation in the Italian Cutlite Penta, aimed at safeguarding its wholly Italian character and DNA, would have been confined to a significant yet minority holding. As things stand today, we are working through the terms of the share purchase agreements required to lock in, in a contractually binding form, what the framework agreement we signed in November <<inaudible>> sets out. The negotiation deadline is March 31. Please, Rohan, could you mute your microphone. I'll carry on -- Mr. Rohan, would you mind muting your microphone?
Bianca Fersini-Mastelloni
operatorRohan, could you please mute — stop your microphone. <<foreign_lang>>
Andrea Cangioli
executiveRight now, we're working through the terms of the share purchase agreement that's required to lock in, in a contractually binding form, the framework agreement that was signed in November. March 31 is the deadline for that negotiation. Regarding where the negotiations stand, there's nothing further I can share. What I can say is that these negotiations are complex, and clearly there are a number of hurdles that have to be cleared, and no party has judged any of those hurdles to be too high, or high enough, to halt the negotiation and issue notice cancelling the framework agreement. So talks continue and are expected to close. Because of the framework agreements and the divestment intention we've disclosed, the way we report our financial results complies with the IFRS 5 accounting standard. Keep in mind that, unless stated otherwise, every financial figure in the press release we issued yesterday and in this presentation is presented under IFRS 5. That means the Chinese business is excluded from the upper part of the income statement, with its assets and liabilities carried in dedicated, segregated lines on the balance sheet. The consolidated financials under IFRS show an EBIT for 2024 that is just above the 2023 EBIT result.
Andrea Cangioli
executiveUnder this representation, our guidance's EBIT metric was achieved. If we had reported using the prior representation, thereby including the Chinese activities across every line of the consolidated income statement, 2024 EBIT would have come in below 2023's EBIT — slightly below — which would have highlighted a modest shortfall against the EBIT guidance. This variance stems, of course, from performance that overall was a bit softer than anticipated, particularly within the laser cutting business unit. But at the bottom line, we can also point to a couple of specific, unexpected events that kept Q4 2024 EBIT from being high enough to reach the annual target under the former presentation of the financials and to beat 2023's fourth quarter EBIT on the full consolidated representation. The first factor was the worsening of the situation at our Japanese subsidiary Withus, together with the financial downturn of its largest customer, which continues to weigh on its activity and income beyond the allowances we had already booked in previous quarters. Incidentally, in early 2025, we ultimately chose to divest control of Withus, which is no longer part of the group's consolidation perimeter.
Andrea Cangioli
executiveThen, there was an unfavorable court ruling in the dispute that Penta Laser Zhejiang customer <<inaudible>> brought — they were contesting whether the complex production line was compliant with contractual specifications, and that line was complete with laser cutting systems plus automatic material handling and sorting, all of which Penta had installed at the customer's facility — and that ruling compelled us to record extra allowances of roughly EUR 2 million. Beyond the guidance metric, we're happy with how we did in the medical sector for 2024, where revenue grew about 4% year on year. That's particularly worth praising considering overall market conditions, which were less favorable than in prior years. In particular, the U.S. market for medical aesthetic application has reportedly been contracting, as shown by weak results at a number of competitors. Our broad product range and distribution channels let the group effectively steer through the difficulties encountered in specific application segments and with certain distributors in the U.S. territory in 2024. As always, new product launches were a key driver of our success. Let me mention here DEKA's RedTouch for pigmented lesions and melasma. DEKA ONDA PRO, which represents the evolution of a body contouring device into a skin tightening and rejuvenation device for facial anti-aging treatments.
Andrea Cangioli
executiveindistinct Red Edition MeDioStar is reshaping how diode-based hair removal is done, and Quanta System Magneto is establishing a fresh benchmark for efficient store management in urology. Conversely, our Industrial sector's results left us less than satisfied, yet we kept putting money into innovation and stronger distribution for the companies serving the systems market for manufacturing. Customized and special-purpose systems are being engineered and produced, and they now account for a growing portion of overall sales in both marking and cutting. We have established distribution subsidiaries in a number of European countries to boost our selling and service capability, and those are beginning to contribute meaningfully to revenue and profit. Enrico will walk through the specifics of how our business segments and business areas performed. Before he begins his presentation, though, I want to note that revenues from the art conservation business passed EUR 1 billion in 2024 for the first time. Financially this is fairly immaterial, and the unit -- the business unit P&L is hardly above breakeven. Still, everyone at the EL.En group takes great pride in this milestone, since it demonstrates our commitment to the social application of our technologies and shows how well our technology performs in that regard.
Andrea Cangioli
executiveAlso, our sustainability policies—which I always like to mention and feel I must mention—reaffirm our dedication to sustainable development, and environmental and social responsibility are increasingly turning into a core element of how we operate. In my view, one of the clearest practical examples is the work we do in art conservation. This also lets me wrap up this part of my remarks by pointing out that every one of our anti-aging applications helps improve the well-being of our end customers. And although sustainability and ESG don't appear to be especially favored or fashionable these days, I believe it's worth emphasizing that this sort of sustainability approach has always been, and will continue to be, a foundation of our business development. Enrico, thank you. Please go ahead.
Enrico Romagnoli
executiveThank you, Andrea. Good morning, everyone. I'll offer a few remarks on the latest financials. As Andrea already noted, both 2024 and 2023 have been drawn up under IFRS accounting principles, with the contribution of the Chinese industrial cutting division reclassified in the asset liabilities and in the income statement results from discontinued operation, for the current year and the prior one alike, given the ongoing negotiation for the sale of the cutting division. The 2024 financial year closed with consolidated revenues of EUR 565.8 million, a slight decline of 1.8% compared to the 2023. The medical sector recorded a positive recovery quarter after quarter with an overall revenue increase at the end of the year of 4.6% and 11.4% increase in the fourth quarter compared to the same period in 2023. In contrast, the Industrial sector continued to suffer due to the weakness of the Italian market with a quarterly revenue decline of 33%, leading to an annual reduction of 15.3%. Gross margin was EUR 245.6 million, an increase of 4.6% compared to the EUR 234.8 million as of December 2023, with a recovery in sales margin from 40.8% to 43.4%. The improvement recorded was based on a favorable sales mix characterized by an increase in sales in the Medical sector, which has higher margins amid the decline in the Industrial sector.
Enrico Romagnoli
executiveOn top of that, the geographic revenue breakdown within the Industrial segment — with the Italian market declining and exports rising at high margins — helped drive stronger overall profitability. Gross margin also gained due to EUR 1.9 million, equivalent to 0.3 percentage point of turnover, from insurance proceeds and government reimbursement tied to damage from the Campi Bisenzio flood in November 2023, already booked in the first half of 2024. Operating expenses went up, with their share of sales climbing from 8.7% to 9.7%. The key drivers are sales and marketing costs for trade fairs and Congress incurred by both the medical and industrial companies, along with R&D expenses. Staff cost rose in value by EUR 6.2 million, up 6.8%, and its impact on sales moved from 16.1% to 17.5%. The national cost for stock option plans for employees came to EUR 2.1 million in 2024 versus EUR 1.6 million in the first half of 2023. EBITDA stood at EUR 91.8 million, in line with the EUR 92.2 million as of December 2023. Its impact on revenue edged up to 16.2% in 2024 from 16% in 2023. Depreciation and provision costs fell from EUR 15.9 million to EUR 15.5 million, with the impact on turnover steady at 2.4%.
Enrico Romagnoli
executiveEBIT came in positive at EUR 78.3 million, a slight gain over EUR 78.2 million last year, with an EBIT margin of 13.8% versus 13.6% the year before. Financial management posted a positive net result of EUR 0.8 million, a significant improvement from last year's negative EUR 0.4 million, partly thanks to positive foreign exchange differences but mainly due to financial income of plus EUR 1.4 million, arising from management of the cash held particularly by <<inaudible>>. The exit of private equity funds from Penta Laser Zhejiang meant the company's IPO in the Chinese market could not be completed. And under the contractual clauses set out in 2019 for the purchase of shares in Penta Zhejiang, listing by November 2024 was a condition for payment of an earn-out of EUR 5 million to the minority partner liquidated at the end of 2019. As a result, the financial liability was eliminated in Ot-las, the holding company of the Chinese entities, with the related income recognized. The result before taxes shows a positive balance of EUR 84.1 million against EUR 77.8 million for 2023, an increase of 8%. The tax burden for the year benefited from the agreement EL.En signed with the tax office for renewal of the so-called patent box for the period 2020-'24.
Enrico Romagnoli
executiveThat one-time gain came to roughly EUR 3 million. The net result from discontinued operations relates to Penta Laser Zhejiang and its Chinese subsidiaries, and it came in as a loss of EUR 3.5 million. If you set aside the capital gain on the sale of 100% of the shares of Cutlite Penta to Ot-las, which took place in August, the consolidated loss of the Chinese cutting division rose from EUR 3.5 million to EUR 10.4 million of growth. And that figure sits within the discontinued operation. The group ended the 2024 financial year with net income of EUR 51.6 million, versus EUR 48.2 million the year before, an increase of 7%. Turning to the balance sheet. It is likewise drawn up under IFRS 5, and the contribution of the Chinese industrial cutting division has been reclassified into assets and liabilities from discontinued operation, for both the current year and the prior year. We can observe a decline in noncurrent assets, driven mainly by the disposal, during Q2 of 2024, of the mid-long-term liquidity investment in insurance policy, at a fair value of EUR 16 million. And over the year, we saw strong cash generation.
Enrico Romagnoli
executiveBy year-end, net financial position came in at EUR 110.6 million, up from EUR 60 million at the start of the year, which reflects solid financial stability for the group. Capital expenditure for 2024 was EUR 13.3 million, compared with EUR 11.6 million in 2023. The group produced cash from operating activity. And during the year, net working capital went down. We saw a one-off positive contribution to net financial position stemming from elimination of the financial liability tied to the earn-out for the EUR 5 million already mentioned earlier, as well as from disposal of long-term investment in insurance policies amounting to EUR 16 million. The remaining amount of this type of investment, recorded in noncurrent assets, is still EUR 7.5 million. During the year, capital expenditure was EUR 15.3 million, and we paid EUR 17 million in dividends. The proposed dividend for payment in May 2025 was EUR 0.22, for a total disbursement of EUR 17.6 million. In the <<inaudible>> regarding revenue breakdown by business, sales in the Medical sector rose 5% in 2024, driven by the good performance delivered in Q3 and Q4 2024.
Enrico Romagnoli
executiveIn Industrial sales, the outcome was the reverse, with a 15% decline that came largely from the cutting division. On the Medical side, higher medical sales were chiefly powered by post-sales revenue, which came in at EUR 79.6 million, up 14%. As for revenue from Systems, the quickest expansion showed up in the Aesthetic sector, rising 4% to roughly EUR 235 million, versus EUR 226 million a year earlier. Helped by a very strong fourth quarter, the Therapy segment likewise posted 2% year-on-year growth, beating the revenue figure for 2023. Surgical sales were flat, though a substantial lift came from optical fibers used as a consumable in urological surgery, which account for 14% of sales in the goods and after-sale service segment. The Industrial sector saw an overall drop of roughly 15%. Within Industrial, that 15% overall decrease is attributed primarily to the Cutting segment, which fell 24%. The Marking segment posted 6% growth, and the strongest revenue growth was recorded in post-sale service, totaling EUR 17 million, a 19% increase — a direct consequence of the sharp rise in the number of systems installed over the last 2 years.
Enrico Romagnoli
executiveFor the laser source, that was down 17%. Looking geographically, Europe and the Rest of the World delivered our strongest growth. Italy remained soft, especially in Industrial, where sales fell 40%. In contrast, Italy's medical market grew 3%. Medical in Europe was up 6%, and Rest of the World sales rose 3%. Industrial put in a strong showing internationally, with solid growth in Europe of plus 10% and chiefly in the Rest of the World, driven mainly by rapid expansion across all other markets, particularly the U.S. Andrea, would you go ahead and comment on the guidance?
Andrea Cangioli
executiveThank you, Enrico. Thanks so much. Now, regarding the 2025 guidance, we aimed to reflect accurately in our press release the sentiment with which our 2025 budget and forecast were prepared, as well as the sentiment we currently hold as we approach this new year. As you're aware, our forecast can't be built on fixed orders, because we don't have — and never have had — visibility extending beyond a few months in our order books to set the guidelines for full-year financial results. The projections we outlined at the end of last year combined an extrapolation of the trend from the most recent months with forecasts concerning the local and world economy, and they subsequently factored in a good degree of optimism. As we've observed, the 2024 trend showed a progressive strengthening of the medical market and a rebalancing of demand in the industrial market, particularly in Italy, following a very tough and weak year. As of today, roughly 3 months later, we've been able to verify that the sales and order bookings trend across the first 2 months aligns with those expectations — perhaps a little weaker than expected on the U.S.
Andrea Cangioli
executiveThat market is positive, though. Still, the picture for the remainder of the year is trickier, given the continuing conflicts and instability in international political relations. Those have, for now, made central banks more cautious about cutting interest rates, which naturally affects how able and willing our customers are to fund their capital goods investments. They have also weakened the U.S. dollar and produced forecasts of a slowdown in the U.S. economy. Against this highly uncertain economic backdrop, we chose to build more prudence into our guidance. We anticipate—we plan—to deliver revenue growth, especially in the industrial sector, along with operating results in line with those of 2024. Calling the expected industrial-sector growth what it is reflects the fact that in the medical sector, revenues will take a hit from the departure of our Japanese subsidiary, which accounted for more than EUR 10 million of revenue in the medical business in 2024. On top of that, in 2025 we will have to absorb a drop in sales to Cynosure, one of our long-standing customers, following its acquisition by Korean Funhan and its merger with the Korean medical laser maker Lutronic, which will ultimately supply Cynosure with the high-power alexandrite lasers used for hair removal—<<inaudible>> has been supplying those to them over the last year.
Andrea Cangioli
executiveBefore I close, I want to say again that I have confidence in how our group keeps innovating and renewing itself, consistently and continuously, so that we can meet and get past the challenges in front of us and grab the opportunities our markets are offering. That wraps up what we had prepared, and now we're ready for your questions.
Giovanni Selvetti
analystAlright, I'll begin, if that works for everybody.
Bianca Fersini-Mastelloni
operatorYeah, we'll take a question from Giovanni Selvetti at Berenberg.
Giovanni Selvetti
analystLet me start with the legal dispute. Could you give us a clearer picture of what actually happened? From what I recall, some provision had already been set aside for that dispute in anticipation of a possible loss. And now I see an extra charge of EUR 2 million, which is not exactly small. So what happened there? And in a way, is this bad news in the sense that, sure, it's now lost, but at least it's something that gets resolved as you come out of the negotiation with the possible acquirer of the Chinese company? Then, maybe — I don't know how much you can say — but staying on China, what drove the deterioration in the last quarter, and how will that affect the chances of the possible deal? And probably the third one is about the guidance. I mean, I understand there are several variables on the plate, right, with possible tariffs and so on and so forth. But how can you think of raising revenues without raising EBIT, in a sense? So if you could elaborate a bit more.
Giovanni Selvetti
analystYou brought up the possibility of losing some revenue tied to Cynosure. So could you put a number on what Cynosure's revenues are right now, and what you expect going forward?
Andrea Cangioli
executiveAll right, on the legal side — you're correct. We set aside a sizable provision in the prior year already. Enrico might give you a sharper figure, but my recollection is that it came to about EUR 2.5 million. What we're dealing with here is a really big plant that we supplied to a customer. The supply itself was on the order of EUR 6 million. And that supply happened several years back. So, I mean, the customer didn't want to install it, and there were a number of problems during installation, which pushed the installation back. When they brought suit against us in early 2024, we worked out a provision assuming a certain outcome to the dispute — one where we figured we'd receive some form of acknowledgment for the work we had done. Then, quite surprisingly, the ruling came out entirely against Penta Laser Zhejiang, and so we needed to book an additional allowance to cover not just what we had judged to be the potential cost of a ruling that might go against us but not entirely so — instead, we are providing for a ruling that goes fully against us. We are appealing, but as things stand right now, that's what we have to record as an allowance against the sale. As for the sale of the company, naturally, there are several matters that came up prior to the transaction, and the result of the lawsuit falls on us.
Andrea Cangioli
executiveI mean, part of this is already reflected in the price. And if any additional costs hit the company as a result of the lawsuit's consequences, that would fall on us. That's a standard breadth and warranty provision in the sale contract. Conversely, if we were to win the appeal, that would result in either a higher price or a reimbursement to us. Regarding the fact that Chinese performance was negative in the fourth quarter, even more so than previously. Naturally, the impact of this allowance was very significant. So this doesn't affect the current business, because it's no longer current business. We're talking about a supply that was initiated in 2023, which was concluded in mid-2024 and was disputed — excuse me, initiated in 2022, completed in 2023 and disputed in early 2024. So at present, even though it's obvious that the Chinese market is very challenging, this isn't affecting the — or at least this isn't explicitly effectively affecting the deal. On the guidance, yes. I understand your point and your questions. In this year 2024, we had a severe reduction in revenues, but we had a slight reduction in profits.
Andrea Cangioli
executiveUnder the new representation as well, EBIT went up. And in both representations, net profit rose, and that comes from a mix effect. We sold more in Medical. So because Medical carries an average margin that is higher, the consolidated margin got a positive boost. And inside the Industrial business, we sold less in Italy, and Italy carries a lower margin than sales made abroad. In response — as we expect for 2025 — to the downturn in Italy in the Industrial business, we anticipate sales in Italy rising again, and as a result the average margin for the cutting business should decline, or should move in a downward direction because of this event. We also expect the share of industrial revenues to edge up slightly, and that therefore affects the mix. Furthermore — I'm speaking about mixes here — if we go down to the expected profitability of each business, we now have to factor in a weaker dollar, and a weaker dollar, given that we had roughly more than USD 90 million of revenues, also means a lower margin on that piece of business. So in a sense, that answers the question of why you plan to grow revenues and, correspondingly, are not planning to grow profitability.
Andrea Cangioli
executiveThis is essentially the mirror image of 2024, when we brought revenue down without really putting a dent in profitability.
Giovanni Selvetti
analystPerhaps to wrap up, as you mentioned, $90 million. Alright. Alright. And maybe, if you will — on that final question, I didn't receive an answer about how large Cynosure is at present and how much you anticipate that changing?
Andrea Cangioli
executiveWe've never made that number public, but the gap is going to be more than EUR 10 million. <<foreign_lang>>.
Bianca Fersini-Mastelloni
operatorAndrea, there’s a question coming in from Carlo Maritano at Intermonte.
Carlo Maritano
analystI've got a quick follow-up about Cynosure. I'm just wondering whether, in your view, revenue from this client will go to 0 over the long term, or is it simply a matter of the magnitude of revenue booked with this client being reduced? My second question concerns the possible effect of duties. Have you made any sort of estimate of what the impact on you could be if duties are introduced on your machinery? And the third question is about U.S. sales. I'm wondering, looking at the new perimeter in the event of the Chinese disposal, how much of your revenue relates to the U.S. market on your new <<inaudible>>?
Andrea Cangioli
executiveCarlo, I’d put together some remarks about tariffs since I expected that topic would come up. So allow me to address it ahead of any question about tariffs, and I’ll simply lay out what could occur. I realize this may sound obvious, but in our situation, if tariffs are imposed, the main result is that our overseas buyers in a country facing those tariffs pay more when purchasing. Next, that foreign customer will request—or would request—that we offset all or part of the tariff burden they have to carry by giving them a discount on the goods they buy. As a result, how tariffs play out hinges on what we agree with each customer, and it can range between 2 extremes: on one end, our customer simply faces higher costs, which hurts sales volume because it amounts in practice to a price increase. At the other end, we fully absorb the tariffs by discounting what we supply, which translates into a matching decline in margins. In all likelihood, the outcome would fall somewhere in between—either fewer sales at unchanged margins or, put another way, unchanged sales at thinner margins. I don’t have an answer.
Andrea Cangioli
executiveI'm aware that certain of our U.S. customers volunteered to back their country's policy by covering part of the tariffs, if they would be charged. But as I just mentioned, that doesn't mean there's no effect, because if they volunteer to pay them, they'll have to raise prices in the market, and they'll probably see a decrease in volumes. But we don't know anything about tariffs and whether we will be subjected to them and how much the tariffs would be imposed, and this concerns the U.S. And then we don't know what will happen in other markets as an answer or a reaction to the imposition of tariffs on the United States. So what I can say and what we said is that we are not factoring in any effect due to tariffs in our projections that we shared with you with our guidance. Concerning Cynosure, the point is that for what concerns the specific product we are providing them today, we probably will see a decline getting to an end of the supply. Then we will continue to supply spare parts, which is a few millions per year because spare parts, but also this will be declining over the time.
Andrea Cangioli
executiveThat doesn’t mean we can’t keep a solid relationship with Cynosure and have them interested in future development of new products that their own technology cannot create but that we can supply. That has occurred multiple times. And I don’t see any reason it couldn’t occur once more, though it simply isn’t planned at this point. As for sales volumes into the United States, I already gave the sales figure when answering the earlier question from Giovanni Selvetti. And the rough scale of sales into the U.S. market — it is a little bit — it is just under EUR 90 million, 9-0, more or less, in 2024.
Andrea Bonfà
analystIf I may, I'll take my turn here. Are you able to hear me?
Andrea Cangioli
executiveCorrect.
Andrea Bonfà
analystTo revisit the duty question briefly — you touched on this during earlier calls. Could you give a quick recap of how competition looks when it comes to local production from a U.S. competitor, let's say? My recollection is that the bulk of your products are made abroad. I mean, most of your industry products are manufactured overseas — Italy, Europe, Israel, Korea, possibly. So just a short recap of where you stand competitively if the client cannot find local content, or if no alternative exists?
Andrea Cangioli
executiveAndrea: Yes, that's a fair point. When it comes to the industrial market, the product we offer has no meaningful U.S. manufacturers or supply behind it. So if tariffs were imposed, the result would be that, since we serve the manufacturing industry, the cost for that industry would go up, with no benefit going to any local manufacturer. That's the industrial side. On the Medical side, U.S. manufacturers do exist, but in our view probably more than 2/3 of the U.S. market is supplied by manufacturers located outside the United States. And it's rather ironic, actually. My impression is that a number of U.S. manufacturers are in fact producing in Mexico. So they're American companies, but they're relying on third-party manufacturers based in Mexico. That means they wouldn't be exempt from tariffs — or perhaps they already aren't exempt for this. Broadly speaking, I believe that imposing tariffs on most of our products would be bottom line punitive for U.S. customers and consumers, with no particular benefit to U.S. manufacturers competing in the same business, aside from a handful of them, which in any case represent a small share of the market in the United States today.
Bianca Fersini-Mastelloni
operatorAndrea, right now there are no further questions in our queue.
Giovanni Selvetti
analystIf that's alright, I'd like to ask a few follow-up questions.
Andrea Bonfà
analystApologies — I actually wasn’t done yet, sorry.
Andrea Bonfà
analystSo, over to you, Andreas.
Andrea Bonfà
analystRight, and just to follow up quickly on that: the EUR 90 million in sales you brought up earlier — does that figure cover just medical, or does metal laser cutting get included in it as well?
Enrico Romagnoli
executiveEvery one of those sales is included in that figure.
Bianca Fersini-Mastelloni
operatorGo ahead, Giovanni.
Giovanni Selvetti
analystI was just wrapping up. Well, maybe I have one more question, perhaps to follow up regarding the competitive landscape, because it's true that in some sense, the partnership with Cynosure may decelerate somewhat owing to the merger they had. Yet at the same time, I could see that a few days ago, Cutera filed for bankruptcy. So I was wondering, since this was the main player for the acne treatment, whether in some way this could give you a boost to be the only major player there. And more of a general question, do you see the industry consolidating further going forward?
Andrea Cangioli
executiveSure, there could be additional consolidation. In our business, consolidation is difficult. From what we hear, the initial year of Lutronic and Cynosure combining has largely not worked out — but bringing companies in our group together and achieving successful consolidation is very complex. Still, additional consolidation is possible. The Cutera bankruptcy isn't really a bankruptcy. It is a formal bankruptcy, yet it's a clever move by a group of investors who are delisting the company, seizing control of it, and freeing the company from a very large debt it owes mainly to themselves. So they are writing off a large portion of their investment, but they are putting in a smaller amount of money to become the sole shareholders of the company and to make it stronger for its actual size. So when we read the news, we thought that, let's say, a competitor was leaving the market, exiting the market. But in fact, it's not a bankruptcy, but it's a Chapter 11, which means it's a reorganization of the financial liabilities and of the share capital of the company in order for the company to survive.
Andrea Cangioli
executiveWhat's left of Cutera then is that the way they distribute their acne device is the wrong approach, but the acne device itself, along with how they position it in the market, won't be taken off the table.
Giovanni Selvetti
analystAll right, and maybe one more question on the back of this — even with all that's happened, the cash position looks pretty strong. It nearly doubled over the year. So I'm curious whether you're thinking about returning more, say by speeding up the buyback, or whether you'd rather keep it where it is — a, for more acquisitions down the road, or b, for investments you feel are necessary?
Andrea Cangioli
executiveI mean, we're also looking at this matter in terms of the potential cash that could come in, which of course would happen once we close — upon finalizing the negotiation — the deal to sell the Chinese company, and let's say, so we'll have additional cash coming in. We don't intend to make M&A activity a specific target as a goal for transforming our company. We'll keep investing in the internal structures of our companies so they can grow more quickly and to pursue rapid internal growth, probably hopefully quicker than the one we've been able to guide you to today. And we might also think about paying richer dividends or other capital transactions, but we have no firm plan and at this moment we can't disclose anything about uses of cash other than the use for internal and progressive investment aimed at internal and progressive growth of our group.
Bianca Fersini-Mastelloni
operatorAndrea, right now there are no additional questions in our queue. If any investors are still on the line, I'd like to check whether anyone has anything else to ask. Any further questions from investors? No. All right, that's it for questions. Ladies and gentlemen, this conference has concluded. Should you have matters to look into later on, feel free to reach out to Enrico Romagnoli, and we'll gladly respond to whatever you need. Thanks for joining this conference, and we look forward to having all of you back next time. Good afternoon, everyone. Bye.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete EL.En. S.p.A. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to EL.En. S.p.A. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in EL.En. S.p.A. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.